These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1350 related items for PubMed ID: 15323576

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 3. Apomorphine: an underutilized therapy for Parkinson's disease.
    Poewe W, Wenning GK.
    Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
    [Abstract] [Full Text] [Related]

  • 4. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A.
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [Abstract] [Full Text] [Related]

  • 5. [Apomorphine in off state--clinical experience].
    Rudzińska M, Szczudlik A.
    Neurol Neurochir Pol; 2007 Sep; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
    [Abstract] [Full Text] [Related]

  • 6. Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
    Henriksen T.
    Neurodegener Dis Manag; 2014 Sep; 4(3):271-82. PubMed ID: 25095821
    [Abstract] [Full Text] [Related]

  • 7. Apomorphine in the treatment of Parkinson's disease.
    Hagell P, Odin P.
    J Neurosci Nurs; 2001 Feb; 33(1):21-34, 37-8. PubMed ID: 11233359
    [Abstract] [Full Text] [Related]

  • 8. [Apomorphine in the treatment of Parkinson's Disease].
    Dressler D.
    Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
    [Abstract] [Full Text] [Related]

  • 9. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ, Turner K, Lees AJ.
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A, Turner K, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [Abstract] [Full Text] [Related]

  • 12. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, Pahwa R, Leinonen M, Bhargava P, Sciarappa K, Navia B, Blum D, CTH-300 Study investigators.
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Continuous dopaminergic stimulation in Parkinson's disease.
    Obeso JA, Luquin MR, Vaamonde J, Grandas F, Martinez Lage JM.
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
    Markham A, Benfield P.
    CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
    [Abstract] [Full Text] [Related]

  • 17. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
    Bhidayasiri R, Chaudhuri KR, LeWitt P, Martin A, Boonpang K, van Laar T.
    Clin Neuropharmacol; 2015 Apr; 38(3):89-103. PubMed ID: 25970277
    [Abstract] [Full Text] [Related]

  • 18. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
    Gancher ST, Woodward WR, Nutt JG.
    Clin Neuropharmacol; 1996 Feb; 19(1):59-64. PubMed ID: 8867518
    [Abstract] [Full Text] [Related]

  • 19. Apomorphine in patients with Parkinson's disease.
    Muguet D, Broussolle E, Chazot G.
    Biomed Pharmacother; 1995 Feb; 49(4):197-209. PubMed ID: 7669939
    [Abstract] [Full Text] [Related]

  • 20. Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation.
    Elia AE, Dollenz C, Soliveri P, Albanese A.
    Eur J Neurol; 2012 Jan; 19(1):76-83. PubMed ID: 21645174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.